Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca Details Deep R&D Cuts

by Lisa M. Jarvis
March 8, 2010 | A version of this story appeared in Volume 88, Issue 10

Following a January announcement of plans for deep R&D cuts, AstraZeneca has revealed which facilities and therapeutic areas will be affected. The company is ending discovery research in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression and anxiety, hepatitis C, and vaccines other than respiratory syncytial virus and influenza. In the U.K., Astra­Zeneca plans to close its Leices­ter­shire and Cambridge sites, affecting roughly 1,000 researchers, and end pharmaceutical development work at the Avlon facility near Bristol. AstraZeneca will close its Lund, Sweden, site. It will also end discovery research in Wilmington, Del., affecting some 550 scientists.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.